IL156436A0 - Thiazole derivatives for treating ppar related disorders - Google Patents

Thiazole derivatives for treating ppar related disorders

Info

Publication number
IL156436A0
IL156436A0 IL15643601A IL15643601A IL156436A0 IL 156436 A0 IL156436 A0 IL 156436A0 IL 15643601 A IL15643601 A IL 15643601A IL 15643601 A IL15643601 A IL 15643601A IL 156436 A0 IL156436 A0 IL 156436A0
Authority
IL
Israel
Prior art keywords
related disorders
thiazole derivatives
treating ppar
ppar related
treating
Prior art date
Application number
IL15643601A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL156436A0 publication Critical patent/IL156436A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15643601A 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders IL156436A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders

Publications (1)

Publication Number Publication Date
IL156436A0 true IL156436A0 (en) 2004-01-04

Family

ID=9905492

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15643601A IL156436A0 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
IL156436A IL156436A (en) 2000-12-20 2003-06-12 Thiazole derivatives and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156436A IL156436A (en) 2000-12-20 2003-06-12 Thiazole derivatives and pharmaceutical preparations containing them

Country Status (27)

Country Link
EP (1) EP1343773B1 (enExample)
JP (1) JP4209681B2 (enExample)
KR (1) KR100815022B1 (enExample)
CN (1) CN1252057C (enExample)
AR (1) AR035522A1 (enExample)
AT (1) ATE344253T1 (enExample)
AU (1) AU2002246713B2 (enExample)
BR (1) BR0116370A (enExample)
CA (1) CA2432188A1 (enExample)
CY (1) CY1105915T1 (enExample)
CZ (1) CZ20031737A3 (enExample)
DE (1) DE60124302T2 (enExample)
DK (1) DK1343773T3 (enExample)
ES (1) ES2274914T3 (enExample)
GB (1) GB0031107D0 (enExample)
HU (1) HUP0400837A3 (enExample)
IL (2) IL156436A0 (enExample)
MX (1) MXPA03005699A (enExample)
MY (1) MY136685A (enExample)
NO (1) NO20032801L (enExample)
NZ (1) NZ526543A (enExample)
PL (1) PL365797A1 (enExample)
PT (1) PT1343773E (enExample)
SI (1) SI1343773T1 (enExample)
TW (1) TWI292759B (enExample)
WO (1) WO2002062774A1 (enExample)
ZA (1) ZA200304679B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL152979A0 (en) 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
AU2004247355A1 (en) 2003-06-06 2004-12-23 F. Hoffmann-La Roche Ag Aniline derivatives
BRPI0412236A (pt) 2003-07-02 2006-09-12 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
EP1856072A4 (en) * 2005-02-25 2009-10-21 Seoul Nat Univ Ind Foundation THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND PROCESSES FOR THE PRODUCTION THEREOF
JP5191744B2 (ja) * 2005-02-25 2013-05-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US8519145B2 (en) 2006-12-02 2013-08-27 Seoul National University Industry Foundation Aryl compounds as PPAR ligands and their use
BRPI0807023A2 (pt) * 2007-01-08 2014-04-22 Seoul Nat Univ Ind Foundation Composto de tiazol como ligante de ppard e produto farmacêutico, cosmético e alimento saudável dele composto
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CN102781924A (zh) * 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
JP2004518702A (ja) 2004-06-24
HK1059925A1 (en) 2004-07-23
DE60124302T2 (de) 2007-05-03
KR20030072571A (ko) 2003-09-15
ZA200304679B (en) 2004-10-04
CY1105915T1 (el) 2011-04-06
IL156436A (en) 2008-06-05
WO2002062774A1 (en) 2002-08-15
SI1343773T1 (sl) 2007-04-30
EP1343773B1 (en) 2006-11-02
MY136685A (en) 2008-11-28
NZ526543A (en) 2004-11-26
EP1343773A1 (en) 2003-09-17
JP4209681B2 (ja) 2009-01-14
PT1343773E (pt) 2007-02-28
HUP0400837A2 (hu) 2004-08-30
ES2274914T3 (es) 2007-06-01
AR035522A1 (es) 2004-06-02
DE60124302D1 (de) 2006-12-14
TWI292759B (en) 2008-01-21
NO20032801D0 (no) 2003-06-19
CZ20031737A3 (cs) 2003-10-15
HUP0400837A3 (en) 2007-11-28
MXPA03005699A (es) 2003-10-06
KR100815022B1 (ko) 2008-03-18
CA2432188A1 (en) 2002-08-15
ATE344253T1 (de) 2006-11-15
BR0116370A (pt) 2003-12-09
GB0031107D0 (en) 2001-01-31
CN1252057C (zh) 2006-04-19
DK1343773T3 (da) 2007-02-05
AU2002246713B2 (en) 2004-09-09
CN1527822A (zh) 2004-09-08
PL365797A1 (en) 2005-01-10
NO20032801L (no) 2003-08-04

Similar Documents

Publication Publication Date Title
PL365797A1 (en) Thiazole derivatives for treating ppar related disorders
HRP20020962A2 (en) Benzothiazole derivatives
IL155093A0 (en) Morpholin-acetamide derivatives for the treatment on inflammatory diseases
IL161623A0 (en) Nicotin-or isonicotin benzothiazole derivatives
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
PL370978A1 (en) Benzothiazole derivatives
EP1328186A4 (en) METHODS OF TREATING VARIOUS EYES DISEASES
PL350050A1 (en) Acyl derivatives which treat vla-4 related disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
AU8298801A (en) Methods for treating atopic disorders
PL358481A1 (en) 6-hydroxy-indazole derivatives for treating glaucoma
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
IL152190A0 (en) Substituted styryl benzylsulfones for treating proliferative disorders
EG24462A (en) Compounds for treating fundic disaccomodation
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
PL373947A1 (en) Benzothiazole derivatives
AU1603401A (en) Pyranoindoles for treating glaucoma
AU8339301A (en) Compounds for the treatment of addictive disorders
AU5567501A (en) Disulfide derivatives useful for treating allergic diseases
AU8173801A (en) Indole derivatives useful for the treatment of cns disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
PL358966A1 (en) Indole derivatives useful for the treatment of cns disorders
AU2001272902A1 (en) Treating musculoskeletal disorders using lp85 and analogs thereof

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted